A precision medicine approach to metabolic therapy for breast cancer in mice

Ngozi D. Akingbesote; Aaron Norman; Wanling Zhu; Alexandra A. Halberstam; Xinyi Zhang; Julia Foldi; Maryam B. Lustberg; Rachel J. Perry

doi:10.1038/s42003-022-03422-9

Communications Biology (May 2022)

A precision medicine approach to metabolic therapy for breast cancer in mice

Ngozi D. Akingbesote,
Aaron Norman,
Wanling Zhu,
Alexandra A. Halberstam,
Xinyi Zhang,
Julia Foldi,
Maryam B. Lustberg,
Rachel J. Perry

Affiliations

Ngozi D. Akingbesote: Department of Celullar and Molecular Physiology, Yale University School of Medicine
Aaron Norman: Department of Celullar and Molecular Physiology, Yale University School of Medicine
Wanling Zhu: Department of Celullar and Molecular Physiology, Yale University School of Medicine
Alexandra A. Halberstam: Department of Celullar and Molecular Physiology, Yale University School of Medicine
Xinyi Zhang: Department of Celullar and Molecular Physiology, Yale University School of Medicine
Julia Foldi: Department of Internal Medicine (Hematology/Oncology), Yale University School of Medicine
Maryam B. Lustberg: Department of Internal Medicine (Hematology/Oncology), Yale University School of Medicine
Rachel J. Perry: Department of Celullar and Molecular Physiology, Yale University School of Medicine

DOI: https://doi.org/10.1038/s42003-022-03422-9
Journal volume & issue: Vol. 5, no. 1
pp. 1 – 11

Abstract

Read online

Mice with breast cancer driven by mutations upstream of the PI3K/Akt insulin signaling pathway are found to be responsive to dapagliflozin, while those driven by mutations downstream of PI3K/Akt or in pathways with other driver mutations did not.

Published in Communications Biology

ISSN: 2399-3642 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science: Biology (General)
Website: https://www.nature.com/commsbio/

About the journal